Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Protein Effect||no effect|
|Gene Variant Descriptions||FGFR2 over exp indicates an over expression of the Fgfr2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.|
|Associated Drug Resistance|
|Category Variants Paths|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 amp FGFR2 over exp||stomach cancer||sensitive||Infigratinib||Preclinical - Pdx||Actionable||In a preclinical study, Truseltiq (infigratinib) decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).||27401245|
|FGFR2 amp FGFR2 over exp||stomach cancer||sensitive||AZD4547||Preclinical - Pdx||Actionable||In a preclinical study, AZD4547 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).||27401245|
|FGFR2 amp FGFR2 over exp||colon cancer||sensitive||Rogaratinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, a colon cancer cell line xenograft model with FGFR2 amplification and FGFR2 overexpression demonstrated antitumor efficacy when treated with Rogaratinib (BAY 1163877), with a partial response in one of eight at one dose and five of eight at a different dose (PMID: 30807645).||30807645|
|FGFR2 amp FGFR2 over exp||stomach cancer||no benefit||Regorafenib||Case Reports/Case Series||Actionable||In a Phase II trial, gastric cancer patients (n=3/35) with FGFR2 amplification and FGFR2 overexpression did not achieve an objective response when treated with Stivarga (regorafenib) (PMID: 33563752).||33563752|